GlassScriptPhysician profile
Felix J Gonzalez
NPI 1700874625
$48,496.14
in general payments reported to CMS, 2019-2025
24 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $615 · 2021: $1,198 · 2022: $144 · 2023: $364 · 2024: $220 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $42K · Travel and Lodging: $2,746 · Food and Beverage: $409 · Gift: $164 · Education: $11.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $42,230.00 |
| Travel and Lodging | $2,746.30 |
| Food and Beverage | $408.87 |
| Gift | $163.62 |
| Education | $11.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $44,976.30 | 2025 | Cooled Rfa |
| Esperion Therapeutics, INC. | $1,395.81 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $442.96 | 2019 | |
| Novo Nordisk INC | $340.93 | 2021-2023 | |
| Braintree Laboratories, INC. | $308.82 | 2019-2024 | Sutab, Suflave |
| Xeris Pharmaceuticals, INC. | $214.64 | 2022-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $145.70 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $137.82 | 2019-2020 | |
| Astellas Pharma US INC | $67.34 | 2019 | |
| Lilly USA, LLC | $58.82 | 2022-2024 | Mounjaro, Zepbound |
| Ironwood Pharmaceuticals, INC | $55.82 | 2019 | |
| Glaxosmithkline, LLC. | $54.58 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Intercept Pharmaceuticals, INC. | $40.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.18 | 2019-2023 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $40.10 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.65 | 2019-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.99 | 2021 | |
| Pfizer INC. | $19.96 | 2021 | |
| Pfizer Pharmaceuticals LLC | $19.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.63 | 2019 | |
| Olympus America INC. | $15.91 | 2021 | |
| Boston Scientific Corporation | $15.11 | 2024 | Resolution 360 Clip |
| Antares Pharma, INC. | $15.07 | 2020 | |
| Phadia US INC. | $13.87 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.